tiprankstipranks
Boston Scientific (BSX)
NYSE:BSX
US Market

Boston Scientific (BSX) Stock Forecast & Price Target

4,198 Followers
See the Price Targets and Ratings of:

BSX Analyst Ratings

Strong Buy
25Ratings
Strong Buy
24 Buy
1 Hold
0 Sell
Based on 25 analysts giving stock ratings to
Boston
Scientific
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BSX Stock 12 Month Forecast

Average Price Target

$103.95
▲(67.67% Upside)
Based on 25 Wall Street analysts offering 12 month price targets for Boston Scientific in the last 3 months. The average price target is $103.95 with a high forecast of $124.00 and a low forecast of $88.00. The average price target represents a 67.67% change from the last price of $62.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"61":"$61","77":"$77","93":"$93","109":"$109","125":"$125"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":124,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$124.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":103.95454545454545,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$103.95</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$88.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[61,77,93,109,125],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62,66.76923076923077,71.53846153846153,76.3076923076923,81.07692307692308,85.84615384615384,90.61538461538461,95.38461538461539,100.15384615384616,104.92307692307692,109.6923076923077,114.46153846153845,119.23076923076923,{"y":124,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62,65.22727272727273,68.45454545454545,71.68181818181819,74.9090909090909,78.13636363636364,81.36363636363636,84.5909090909091,87.81818181818181,91.04545454545455,94.27272727272728,97.5,100.72727272727272,{"y":103.95454545454545,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62,64,66,68,70,72,74,76,78,80,82,84,86,{"y":88,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":101.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.19,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.78,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.41,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.66,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.85,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.72,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.01,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.87,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 66,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.22,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 86,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$124.00Average Price Target$103.95Lowest Price Target$88.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies
$110
Buy
77.42%
Upside
Reiterated
04/02/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Alto Neuroscience, Inc. (NYSE: ANRO)
Erste Group Analyst forecast on BSX
Erste Group
Erste Group
Hold
Assigned
04/01/26
Boston Scientific (BSX) Gets a Hold from Erste Group
Truist Financial Analyst forecast on BSX
Truist Financial
Truist Financial
Buy
Reiterated
03/30/26
Analysts Offer Insights on Healthcare Companies: Tonix Pharma (NASDAQ: TNXP), Alumis Inc. (NASDAQ: ALMS) and Boston Scientific (NYSE: BSX)
Leerink Partners Analyst forecast on BSX
Leerink Partners
Leerink Partners
$95$89
Buy
43.55%
Upside
Reiterated
03/30/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Abbott Laboratories (NYSE: ABT)
Bank of America Securities Analyst forecast on BSX
Bank of America Securities
Bank of America Securities
$105
Buy
69.35%
Upside
Reiterated
03/30/26
Boston Scientific: CHAMPION AF Validates Watchman Safety, Supporting 20% LAAC Growth and Buy Rating
Canaccord Genuity Analyst forecast on BSX
Canaccord Genuity
Canaccord Genuity
$109
Buy
75.81%
Upside
Reiterated
03/30/26
Boston Scientific (BSX) Gets a Buy from Canaccord Genuity
RBC Capital
$115
Buy
85.48%
Upside
Reiterated
03/30/26
Boston Scientific (BSX) Receives a Buy from RBC Capital
Wells Fargo Analyst forecast on BSX
Wells Fargo
Wells Fargo
$94
Buy
51.61%
Upside
Reiterated
03/30/26
Boston Scientific upside scenario unlikely after data, says Wells FargoBoston Scientific upside scenario unlikely after data, says Wells Fargo
Evercore ISI Analyst forecast on BSX
Evercore ISI
Evercore ISI
$96
Buy
54.84%
Upside
Reiterated
03/30/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Needham
$97
Buy
56.45%
Upside
Reiterated
03/30/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Stifel Nicolaus Analyst forecast on BSX
Stifel Nicolaus
Stifel Nicolaus
$90
Buy
45.16%
Upside
Reiterated
03/30/26
Stifel Nicolaus Sticks to Its Buy Rating for Boston Scientific (BSX)
Barclays Analyst forecast on BSX
Barclays
Barclays
$124
Buy
100.00%
Upside
Reiterated
03/29/26
Barclays Sticks to Its Buy Rating for Boston Scientific (BSX)
TD Cowen
$100
Buy
61.29%
Upside
Reiterated
03/29/26
Buy Rating on Boston Scientific’s Watchman FLX Backed by Champion Trial Success and Accelerating LAAC Market Growth
BTIG
$110
Buy
77.42%
Upside
Reiterated
03/29/26
Boston Scientific: Positive on Watchman LAAC as CHAMPION-AF Data Support First-Line Use, Label Expansion, and Upside to Growth
Raymond James Analyst forecast on BSX
Raymond James
Raymond James
$97$88
Buy
41.94%
Upside
Reiterated
03/27/26
Boston Scientific downgraded to Outperform from Strong Buy at Raymond JamesBoston Scientific downgraded to Outperform from Strong Buy at Raymond James
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies
$110
Buy
77.42%
Upside
Reiterated
04/02/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Alto Neuroscience, Inc. (NYSE: ANRO)
Erste Group Analyst forecast on BSX
Erste Group
Erste Group
Hold
Assigned
04/01/26
Boston Scientific (BSX) Gets a Hold from Erste Group
Truist Financial Analyst forecast on BSX
Truist Financial
Truist Financial
Buy
Reiterated
03/30/26
Analysts Offer Insights on Healthcare Companies: Tonix Pharma (NASDAQ: TNXP), Alumis Inc. (NASDAQ: ALMS) and Boston Scientific (NYSE: BSX)
Leerink Partners Analyst forecast on BSX
Leerink Partners
Leerink Partners
$95$89
Buy
43.55%
Upside
Reiterated
03/30/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Abbott Laboratories (NYSE: ABT)
Bank of America Securities Analyst forecast on BSX
Bank of America Securities
Bank of America Securities
$105
Buy
69.35%
Upside
Reiterated
03/30/26
Boston Scientific: CHAMPION AF Validates Watchman Safety, Supporting 20% LAAC Growth and Buy Rating
Canaccord Genuity Analyst forecast on BSX
Canaccord Genuity
Canaccord Genuity
$109
Buy
75.81%
Upside
Reiterated
03/30/26
Boston Scientific (BSX) Gets a Buy from Canaccord Genuity
RBC Capital
$115
Buy
85.48%
Upside
Reiterated
03/30/26
Boston Scientific (BSX) Receives a Buy from RBC Capital
Wells Fargo Analyst forecast on BSX
Wells Fargo
Wells Fargo
$94
Buy
51.61%
Upside
Reiterated
03/30/26
Boston Scientific upside scenario unlikely after data, says Wells FargoBoston Scientific upside scenario unlikely after data, says Wells Fargo
Evercore ISI Analyst forecast on BSX
Evercore ISI
Evercore ISI
$96
Buy
54.84%
Upside
Reiterated
03/30/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Needham
$97
Buy
56.45%
Upside
Reiterated
03/30/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Stifel Nicolaus Analyst forecast on BSX
Stifel Nicolaus
Stifel Nicolaus
$90
Buy
45.16%
Upside
Reiterated
03/30/26
Stifel Nicolaus Sticks to Its Buy Rating for Boston Scientific (BSX)
Barclays Analyst forecast on BSX
Barclays
Barclays
$124
Buy
100.00%
Upside
Reiterated
03/29/26
Barclays Sticks to Its Buy Rating for Boston Scientific (BSX)
TD Cowen
$100
Buy
61.29%
Upside
Reiterated
03/29/26
Buy Rating on Boston Scientific’s Watchman FLX Backed by Champion Trial Success and Accelerating LAAC Market Growth
BTIG
$110
Buy
77.42%
Upside
Reiterated
03/29/26
Boston Scientific: Positive on Watchman LAAC as CHAMPION-AF Data Support First-Line Use, Label Expansion, and Upside to Growth
Raymond James Analyst forecast on BSX
Raymond James
Raymond James
$97$88
Buy
41.94%
Upside
Reiterated
03/27/26
Boston Scientific downgraded to Outperform from Strong Buy at Raymond JamesBoston Scientific downgraded to Outperform from Strong Buy at Raymond James
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Boston Scientific

3 Months
xxx
Success Rate
18/24 ratings generated profit
75%
Average Return
+5.52%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +5.52% per trade.
1 Year
Jayson BedfordRaymond James
Success Rate
41/54 ratings generated profit
76%
Average Return
+14.69%
Copying Jayson Bedford's trades and holding each position for 1 Year would result in 75.93% of your transactions generating a profit, with an average return of +14.69% per trade.
2 Years
xxx
Success Rate
43/54 ratings generated profit
80%
Average Return
+29.44%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 79.63% of your transactions generating a profit, with an average return of +29.44% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BSX Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
1
5
17
17
Buy
52
37
61
69
47
Hold
1
0
0
0
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
53
38
66
86
65
In the current month, BSX has received 64 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. BSX average Analyst price target in the past 3 months is 103.95.
Each month's total comprises the sum of three months' worth of ratings.

BSX Financial Forecast

BSX Earnings Forecast

Next quarter’s earnings estimate for BSX is $0.79 with a range of $0.78 to $0.85. The previous quarter’s EPS was $0.80. BSX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BSX has Performed in-line its overall industry.
Next quarter’s earnings estimate for BSX is $0.79 with a range of $0.78 to $0.85. The previous quarter’s EPS was $0.80. BSX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BSX has Performed in-line its overall industry.

BSX Sales Forecast

Next quarter’s sales forecast for BSX is $5.18B with a range of $5.08B to $5.28B. The previous quarter’s sales results were $5.29B. BSX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year BSX has Performed in-line its overall industry.
Next quarter’s sales forecast for BSX is $5.18B with a range of $5.08B to $5.28B. The previous quarter’s sales results were $5.29B. BSX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year BSX has Performed in-line its overall industry.

BSX Stock Forecast FAQ

What is BSX’s average 12-month price target, according to analysts?
Based on analyst ratings, Boston Scientific’s 12-month average price target is 103.95.
    What is BSX’s upside potential, based on the analysts’ average price target?
    Boston Scientific has 67.67% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BSX a Buy, Sell or Hold?
          Boston Scientific has a consensus rating of Strong Buy which is based on 24 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Boston Scientific’s price target?
            The average price target for Boston Scientific is 103.95. This is based on 25 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $124.00 ,the lowest forecast is $88.00. The average price target represents 67.67% Increase from the current price of $62.
              What do analysts say about Boston Scientific?
              Boston Scientific’s analyst rating consensus is a Strong Buy. This is based on the ratings of 25 Wall Streets Analysts.
                How can I buy shares of BSX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.